Condition | Date Added to the RUSP | Current Procedure Stage |
---|---|---|
X-Linked Adrenoleukodystrophy Note: study ordered by SCR 3 of the 2016 Regular Session (not promulgated, not tested for) | 2015 | 5. Implementation from the lab |
Guanidinoacetate Methyltransferase Deficiency | 2022 | 2. Review by Genetic Diseases Program Advisory Committee |
Mucopolysaccharidosis Type II | 2022 | 2. Review by Genetic Diseases Program Advisory Committee |
Krabbe Disease Note: study ordered by Act 507 of the 2016 Regular Session |
2024 | 1. Recommended Uniform Screening Panel adds screening |
Tracking Louisiana Newborn Screening Conditions
Louisiana’s Newborn Screening Program screens for many different genetic and metabolic disorders through the heel stick screening. All states and territories have a newborn screening program to ensure screening occurs within the first 24-48 hours after birth and that appropriate follow-up education, testing, and care are provided. As medical technologies and treatments advance, it becomes possible to screen for more conditions. Therefore, the National Advisory Committee on Heritable Disorders in Newborns and Children was established to provide advice and recommendations to the Secretary of Health and Human Services (HHS Secretary) on what conditions should be included on a Recommended Uniform Screening Panel. Some states rely on the Recommended Uniform Screening Panel to inform their own state panels.
Additionally, each state defines its own processes for adding conditions. In Louisiana, the conditions on the state newborn screening panel and the laboratories authorized to complete the testing are outlined in the Louisiana Administrative Code40.v.6303. As of February 2024, Louisiana’s standard newborn screening panel approved in the Louisiana Administrative Code 40 includes 34 of the 37 conditions listed in the Recommended Uniform Screening Panel. The procedure for adding new conditions to the Louisiana Newborn Screening Panel is outlined below.
Procedure for Adding New Conditions to the Louisiana Newborn Screening Panel
-
Panel Adds Screening:
-
The National Advisory Committee on Heritable Disorders in Newborns and Children recommends the condition for addition to the Recommended Uniform Screening Panel.
-
The Secretary of Health and Human Services approves the condition for inclusion in the Recommended Uniform Screening Panel.
-
-
Review by the Advisory Committee:
-
The Louisiana Genetic Diseases Advisory Committee meets quarterly to review the science and cost-benefit of adding new conditions.
-
Consideration to add the condition is given to the testing methodology, treatment, and cost.
-
-
Leadership Advancement:
-
The Genetic Diseases Program shares the Genetic Diseases Program Advisory Committee’s recommendations with the Surgeon General and leadership at the Office of Public Health and the Louisiana Department of Health for review and approval.
-
The laboratory prepares for pilots and validations.
-
The Genetic Diseases Program initiates preparation for follow-up systems.
-
-
Legislative Advancement:
-
The department initiates rulemaking for adding the condition to the Newborn Screening Rule (LAC 48.v.6303).
-
The department initiates a request for budget appropriation (if applicable).
-
-
Implement:
-
The Genetic Diseases Program finalizes the process for reporting and follow-up.
-
The laboratory completes validation studies and secures external laboratory support, if needed.
-
Communicate with healthcare providers, systems, advocates, and other constituencies.
-
Testing “goes live” once the updated rule is promulgated.
-
List of Conditions in the Process of Being Added to the Louisiana Newborn Screening Panel
Updated as of October 2025
List of Conditions Currently on the Louisiana Newborn Screening Panel
Learn more about each condition by visiting the Newborn Screening Panel webpage.
Condition | Date Added to the Recommended Uniform Screening Panel | Date Added to the Louisiana Newborn Screening Panel |
---|---|---|
Classic Phenylketonuria | Pre-dates Recommended Uniform Screening Panel | 1964, Act 269 |
Primary Congenital Hypothyroidism | Pre-dates Recommended Uniform Screening Panel | 1978 |
Tyrosinemia, Type I | Pre-dates Recommended Uniform Screening Panel | 2006 |
S,S Disease (Sickle Cell Anemia) | Pre-dates Recommended Uniform Screening Panel | 1972 for Af.Am., 1992 for all |
Classic Galactosemia | Pre-dates Recommended Uniform Screening Panel | 1981 |
S, βeta-Thalassemia | Pre-dates Recommended Uniform Screening Panel | 1992 |
S,C Disease (“mild” form of sickle cell anemia) | Pre-dates Recommended Uniform Screening Panel | 1992 |
Biotinidase Deficiency | Pre-dates Recommended Uniform Screening Panel | 1999, Act 328 |
Congenital adrenal hyperplasia | Pre-dates Recommended Uniform Screening Panel | 2006 |
Cystic Fibrosis | Pre-dates Recommended Uniform Screening Panel | 2007 |
Homocystinuria | Pre-dates Recommended Uniform Screening Panel | 1981, added to the rule in 2006 |
Maple Syrup Urine Disease | 2006 | 1981, added to the rule in 2006 |
Propionic Acidemia | 2006 | 2006 |
Methylmalonic Acidemia (methylmalonyl-CoA mutase) | 2006 | 2006 |
Methylmalonic Acidemia (Cobalamin disorders) | 2006 | 2006 |
Isovaleric Acidemia | 2006 | 2006 |
3-Methylcrotonyl-CoA Carboxylase Deficiency | 2006 | 2006 |
3-Hydroxy-3-Methyglutaric Aciduria | 2006 | 2006 |
Holocarboxylase Synthase Deficiency | 2006 | 2006 |
ß-Ketothiolase Deficiency | 2006 | 2006 |
Glutaric Acidemia Type I | 2006 | 2006 |
Carnitine Uptake Defect/Carnitine Transport Defect | 2006 | 2006 |
Medium-chain Acyl-CoA Dehydrogenase Deficiency | 2006 | 2006 |
Very Long-chain Acyl-CoA Dehydrogenase Deficiency | 2006 | 2006 |
Long-chain L-3 Hydroxyacyl-CoA Dehydrogenase Deficiency | 2006 | 2006 |
Trifunctional Protein Deficiency | 2006 | 2006 |
Argininosuccinic Aciduria | 2006 | 2006 |
Citrullinemia, Type I | 2006 | 2006 |
Severe Combined Immunodeficiency | 2009 | 2018 |
Pompe Disease | 2013 | 2021 Regular Session, Act 305 (implemented January 1, 2022) |
Mucopolysaccharidosis Type I | 2015 | 2021 Regular Session, Act 305 (implemented January 1, 2022) |
Spinal Muscular Atrophy | 2018 | 2021 Regular Session, Act 305 (implemented January 1, 2022) |
Please submit questions about the Louisiana Newborn Screening Panel through this form or email [email protected].